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ABSTRACT
Introduction:  This post-hoc analysis 
compared  the  e f fec t s  o f  swi tch ing 
to  eze t imibe/ s imvas ta t in  10/20  mg
(EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) 
in high-risk hypercholesterolemic patients 
with/without obesity. Methods: Patients 
(n=618) at high-risk for coronary heart 
disease with elevated low-density lipoprotein 
cholesterol (LDL-C) ≥2.59 and ≤4.92 mmol/L, 
while on a statin, entered a 6-week open-
label stabilization/screening period during 
which they continued on the same statin. 
Patients were then randomized 1:1 to double-
blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg
for 6 weeks. Patients were classified as 
non-obese (n=437) or obese (n=180) based 
on body mass index <30 or ≥30 kg/m2,
respectively. Results: EZE/SIMVA was more 
effective than ROSUVA at lowering LDL-C, total 
cholesterol (TC), non-high-density lipoprotein 
cholesterol (non-HDL-C), and apolipoprotein 
(apo) B in the overall population (P<0.001 for 
all). These results were consistent for obese 
and non-obese patients as demonstrated by 
the lack of significant treatment-by-subgroup 
interaction terms for LDL-C, TC, non-HDL-C, 
and apo B (P>0.050 for all). Conclusions: In 
this post-hoc analysis of high-risk patients 
with elevated LDL-C, despite prior use of statin 
therapy, switching to EZE/SIMVA 10/20 mg
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versus ROSUVA 10 mg provided superior 
reductions in LDL-C, TC, and non-HDL-C in 
obese and non-obese patients.
Keywords: apolipoprotein B; ezetimibe; 
low-density lipoprotein; non-high-density 
lipoprotein; obesity; simvastatin; total 
cholesterol; triglycerides
INTRODUCTION
Obesity has reached global epidemic proportions, 
and its prevalence continues to increase in 
many developed countries. Obesity is strongly 
related to the development of vascular diseases 
and metabolic complications.1 Adipose tissue is 
metabolically active, since it contributes to the 
atherogenic dyslipidemia, hyperinsulinemia, 
and hypertension that consequently place obese 
individuals at increased risk of coronary heart 
disease (CHD).
Comprehensive medical management can 
reduce the risk of CHD in obese patients through 
lifestyle modification (eg, diet and exercise) and 
pharmacologic intervention aimed at improving 
control of blood glucose and hypertension, as 
well as the overall lipoprotein profile.
Treatment guidelines for managing 
dyslipidemia have traditionally focused on 
lowering low-density lipoprotein cholesterol 
(LDL-C) levels, which has been proven to 
reduce cardiovascular events and mortality.2 
However, the primary dyslipidemia observed 
in obese patients is often characterized by low 
levels of high-density lipoprotein cholesterol 
(HDL-C), increased levels of non-HDL-C, 
triglycerides (TG), apolipoprotein B-100 (apo B), 
and abnormal LDL composition (ie, increased 
levels of small, dense LDL-C particles).3,4 The 
pathogenesis of the dyslipidemia seen in obese 
patients is likely due to the state of insulin 
resistance resulting from the accumulation 
of excess body fat.5,6 As a result, dyslipidemia 
may be undertreated in patients with obesity 
even following intensive LDL-C-lowering with 
statins. To this end, the 2008 American Diabetes 
Association and American College of Cardiology 
Foundation (ADA/ACC) consensus report 
recommends non-HDL-C and apo B treatment 
targets for managing dyslipidemia in patients 
with elevated cardiometabolic risk, including 
obese patients (Table 1).7
In view of the need to aggressively manage 
atherogenic dyslipidemia, the use of combination 
lipid-lowering therapies may be warranted to 
facilitate the achievement of optimal lipid and 
lipoprotein levels. This post-hoc exploratory 
analysis of data from a previously reported 




































Table 1. Recommended lipid/lipoprotein treatment goals 
for patients with cardiometabolic risk according to 
the joint consensus statement issued by the American 
Diabetes Association and American College of Cardiology 
Foundation.6
*Includes patients with: 1) known cardiovascular disease 
(CVD), or 2) diabetes plus one or more additional major 
CVD risk factors beyond dyslipoproteinemia (ie, smoking, 
hypertension, family history of premature coronary heart 
disease).
†Includes patients with 1) no diabetes or known clinical 
CVD but with two or more additional major CVD risk 
factors, or 2) diabetes with no other major CVD risk 
factors.
Apo B=apolipoprotein B; LDL-C=low-density 
lipoprotein cholesterol; non-HDL-C=non-high-density 
lipoprotein cholesterol.
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active-controlled, 6-week, parallel-group study8 
(NCT00479713; Merck protocol 809) compared 
the lipid/lipoprotein-altering effects of switching 
from a stable dose of statin monotherapy to 
the initial recommended starting doses of 
ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg 
or rosuvastatin (ROSUVA) 10 mg monotherapy 
in high-risk hypercholesterolemic obese (body 
mass index [BMI] ≥30 kg/m2) and non-obese 
patients.
MATERIALS AND METHODS
Patients and Study Design
Patients were deemed to be of high cardiovascular 
risk if they met one or more of the following 
criteria: 1) history of CHD or established vascular 
atherosclerotic disease (ie, peripheral vascular 
disease, ischemic stroke); 2) type 2 diabetes 
mellitus without a history of vascular disease 
and/or with high cardiovascular risk with at 
least 2 CHD risk factors per Framingham criteria; 
3) CHD risk >20% over 10 years as determined 
by the Framingham risk calculation.9
The study enrolled men and women 
≥18 and <80 years of age. At screening, LDL-C 
levels ranged from ≥2.59 and ≤4.92 mmol/L. 
Following a 6-week open-label statin dose 
stabilization run-in phase, eligible patients with 
elevated LDL-C ≥2.59 and ≤4.14 mmol/L, despite 
the continued use of their usual statins, were 
stratified by study center and baseline statin 
dose/potency and randomized 1:1 to double-
blind treatment with EZE/SIMVA 10/20 mg 
or ROSUVA 10 mg for 6 weeks.8 The protocol 
for the original study was approved by the 
institutional review board or ethics committee 
of each participating center, and all patients 
provided written informed consent. All lipid 
and safety laboratory analyses were conducted 
at a central laboratory. Additional details of the 
study design and patient population have been 
reported.8,10
Statistical Analyses 
Efficacy and safety analyses were conducted 
in the overall analysis population, as well as 
within obese and non-obese patient subgroups. 
The overall analysis population consisted of all 
randomized patients with known baseline BMI 
values. The primary efficacy endpoint was the 
effects of treatment on the mean percentage 
change from baseline to the last post-baseline 
measurement in LDL-C. Other efficacy endpoints 
included percent change from baseline in total 
cholesterol (TC), TG, HDL-C, non-HDL-C, 
LDL-C:HDL-C ratio, TC:HDL-C ratio, apo B, and 
high-sensitivity C-reactive protein (hs-CRP). 
The percentage of patients achieving target 
LDL-C (<2.59 and <1.81 mmol/L), non-HDL-C 
(<3.37 and <2.59 mmol/L), and apo B goals (<0.9 
and <0.8 g/L) at study endpoint were assessed.
This subgroup analysis was performed on 
the full-analysis set (FAS) population, which 
included all patients with known baseline 
BMI values who received at least one dose 
of study medication, had a baseline efficacy 
measurement, and had at least one post-
randomization efficacy measurement. Missing 
data were imputed using the last-observation-
carried-forward method. 
Continuous efficacy results for percent 
change from baseline in normally distributed 
parameters ( ie,  LDL- C, TC, HDL-C, 
non-HDL-C, LDL-C:HDL-C ratio, TC:HDL-C 
ratio, and apo B) were analyzed using a 
parametric analysis of variance (ANOVA) 
model with terms for treatment, stratum, 
baseline efficacy variable (categorized based on 
quartiles), study center, obesity status (yes, no), 
and treatment-by-subgroup interaction. Least 
squares means and 95% CIs within each patient 
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subgroup (ie, obese/non-obese) using the above 
model (except the last two terms involving 
subgroup) were computed and used to quantify 
the differences between treatment groups.
Continuous efficacy results for percent 
change from baseline in non-normally 
distributed parameters (ie, TG and hs-CRP) 
were analyzed using an ANOVA model on rank-
transformed data for these efficacy variables 
with terms for treatment, stratum, baseline 
efficacy variable (categorized based on quartiles), 
study center, obesity status, and treatment-by-
subgroup interaction. Differences between 
treatment groups were quantified as differences 
in medians and 95% CIs using Hodges-Lehmann 
estimates within each patient subgroup.
The percentages of patients achieving lipid/
lipoprotein goals at study end were analyzed 
using a logistic regression model with terms for 
treatment, stratum, baseline efficacy variable, 
obesity status, and treatment-by-subgroup 
interaction. Odds ratio estimates and 95% CIs 
using the above model (except the last two terms 
involving subgroup) were computed and used 
to quantify the treatment effect within each 
patient subgroup.
Due to the exploratory nature of this analysis, 
no multiplicity adjustments were employed. 
Between-group differences and treatment-by-
subgroup interaction tests with a P value <0.050 
were considered statistically significant.
The safety analysis was based on the all-
patients-as-treated population of patients with 
known BMI values at baseline who received at 
least one dose of study medication. Adverse 
experiences (AEs) were assessed throughout the 
study. The investigators determined the severity 
of AEs and the relationship to study drug. 
Prespecified AEs of special interest included 
those that were gastrointestinal, gallbladder or 
hepatobiliary related, allergic reaction or rash, 
elevations in alanine aminotransferase and/or 
aspartate aminotransferase ≥3 times the upper 
limit of normal (ULN), and creatine kinase 




Of the 618 patients enrolled, one patient 
had a missing BMI value at baseline and was 
excluded from both the efficacy and safety 
analyses. Within each patient subgroup, the 
baseline demographic and anthropometric 
characteristics were generally well balanced 
across the EZE/SIMVA and ROSUVA treatment 
groups (Table 2). The only exception was finding 
more diabetic patients in the EZE/SIMVA group 
than in the ROSUVA group within the obese 
subgroup. The obese (n=180) and non-obese 
(n=437) subgroups were similar in terms of age, 
race, duration of hypercholesterolemia, blood 
pressure values, and medical history of CHD. 
A greater percentage of women were classified 
as obese, versus men. Obese patients had higher 
mean BMI and fasting plasma glucose values 
at baseline than non-obese patients. Also, 
more obese patients had medical histories of 
hypertension and diabetes than did non-obese 
patients. With regard to lipid/lipoprotein/
biochemical parameters, obese patients had 
higher median baseline TG and hs-CRP levels 
and lower mean HDL-C levels compared with 
non-obese patients (Table 2). Baseline LDL-C 
values were generally similar between treatment 
groups and obesity subgroups.
Effects of Treatment on Lipid/Lipoprotein 
Parameters and hs-CRP
The effects of EZE/SIMVA 10/20 mg and 
ROSUVA 10 mg on plasma concentrations of 
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Age, yr 63.5 ± 9.1 62.0 ± 9.0 63.1 ± 10.2 63.5 ± 10.4
Race 
   White 













Body mass index, kg/m2* 33.6 ± 3.7 33.9 ± 3.4 25.7 ± 2.7 25.8 ± 2.7
LDL-C, mmol/L 3.2 ± 0.4 3.3 ± 0.4 3.2 ± 0.4 3.2 ± 0.4
TC, mmol/L 5.3 ± 0.5 5.4 ± 0.6 5.4 ± 0.6 5.4 ± 0.6
TG, mmol/L† 1.6 ± 0.9 1.6 ± 1.1 1.4 ± 0.8 1.3 ± 0.8
HDL-C, mmol/L 1.3 ± 0.3 1.3 ± 0.3 1.5 ± 0.4 1.5 ± 0.4
Non-HDL-C 4.0 ± 0.5 4.1 ± 0.5 3.9 ± 0.6 3.9 ± 0.6
LDL-C:HDL-C 2.5 ± 0.6 2.6 ± 0.6 2.3 ± 0.6 2.4 ± 0.7
TC-C:HDL-C 4.2 ± 0.9 4.2 ± 0.9 3.8 ± 0.9 3.9 ± 0.9
Apo B, g/L 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
hs-CRP, mg/dL† 0.2 ± 0.3 0.2 ± 0.3 0.1 ± 0.2 0.1 ± 0.2
FPG, mmol/L 6.6 ± 1.7 6.1 ± 1.3 5.6 ± 1.3 5.7 ± 1.5
Duration of hypercholesterolemia, yr 7.9 ± 5.8 8.8 ± 5.6 8.4 ± 5.6 9.4 ± 7.0
Systolic blood pressure, mm Hg 135.4 ± 11.0 134.5 ± 11.7 131.7 ± 12.6 133.2 ± 12.6
Diastolic blood pressure, mm Hg 79.9 ± 7.1 79.0 ± 8.7 77.6 ± 7.1 78.4 ± 7.5
History of hypertension 70 (72.2%) 56 (67.5%) 132 (61.1%) 133 (60.2%)
History of CHD 46 (47.4%) 40 (48.2%) 106 (49.1%) 104 (47.1%)
History of T2DM‡ 51 (52.6%) 31 (37.3%) 49 (22.7%) 51 (23.1%)
Statin potency stratum 
   Low potency§ 













Table 2. Baseline characteristics for randomized obese and non-obese patients.
All data are shown as mean ± SD or n (%), unless otherwise noted.  
*Excludes one randomized patient in the non-obese group with unknown body mass index at baseline.  
†Data shown as median ± SD.  
‡Two randomized patients had unknown diabetes status at baseline, one is obese on EZE/SIMVA and one is non-obese on ROSUVA.   
§Low potency stratum: simvastatin 20 mg, pravastatin 40 mg, fluvastatin 80 mg, atorvastatin 10 mg; high potency stratum: 
simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg.
Apo B=apolipoprotein B; CHD=coronary heart disease; EZE/SIMVA=ezetimibe/simvastatin combination tablet; 
FPG=fasting plasma glucose; HDL-C=high-density lipoprotein cholesterol; hs-CRP=high-sensitivity C-reactive protein; 
LDL-C=low-density lipoprotein cholesterol; ROSUVA=rosuvastatin; SD=standard deviation; T2DM=type 2 diabetes 
mellitus; TC=total cholesterol; TG=triglyceride.
lipids, lipoproteins, and hs-CRP within the 
obese and non-obese subgroups are shown 
in Table 3. Results for the overall population 
are provided for comparative purposes. In 
the overall population, switching from statin 
monotherapy to EZE/SIMVA 10/20 mg compared 
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with ROSUVA 10 mg for 6 weeks resulted in 
significantly larger reductions from baseline in 
LDL-C (10.6%; P<0.001), TC (7.2%; P<0.001), 
non-HDL-C (9.4%; P<0.001), LDL-C:HDL-C (9.5%; 
P<0.001), TC:HDL-C (6.2%; P<0.001) and apo B
(8.1%: P<0.001) at study endpoint (Table 3;
Figure 1). A borderline significantly greater 
reduction in TG was seen, favoring EZE/SIMVA 
therapy (5.1%; P=0.053) (Table 3; Figure 1). Both 
EZE/SIMVA and ROSUVA produced significant 
increases from baseline in HDL-C; however, 
the between-group difference did not reach 
significance. Neither EZE/SIMVA nor ROSUVA 
produced significant within- or between-group 
changes from baseline in hs-CRP (Table 3).
The treatment effects within the subgroups 
were generally consistent with those in the 
overall population as indicated by the absence 
of treatment-by-subgroup interactions for 
all of the lipid/lipoprotein and biochemical 
parameters analyzed (Figure 1). EZE/SIMVA 
10/20 mg was significantly more effective 
than ROSUVA 10 mg at lowering LDL-C, TC, 
non-HDL-C, and TC:HDL-C in both obese 
and non-obese patients (Table 3; Figure 1). 
Significant between-group reductions in 
LDL-C:HDL-C and apo B also were observed 
in non-obese patients favoring EZE/SIMVA 
therapy (Table 3; Figure 1). In obese patients, 
numerically larger reductions from baseline 
in LDL-C:HDL-C and apo B were observed 
with EZE/SIMVA versus ROSUVA therapy; 
however, the between-group differences did 
not reach statistical significance (Table 3;
Figure 2). Treatment with EZE/SIMVA or 
ROSUVA produced significant reductions 
from baseline in TG within the subgroups 
(Table 3; Figure 1). Reductions from baseline 
in TG were numerically larger in the 
EZE/SIMVA group than in the ROSUVA group; 
however, the between-group differences did 
not reach statistical significance. Treatment 
with EZE/SIMVA or ROSUVA produced small 
but significant increases from baseline in 
HDL-C in the non-obese subgroup, whereas 
no significant changes from baseline were 
observed in obese patients (Table 3; Figure 1). 
No significant within- or between-treatment 
group changes from baseline in hs-CRP were 
observed in either subgroup at study endpoint 
(Table 3).
Lipid/Lipoprotein Goal Attainment
In the overall population, significantly higher 
percentages of patients achieved LDL-C levels 
of <2.59 and <1.81 mmol/L (P<0.001 for both 
targets; Figure 2), non-HDL-C levels of <3.37 
and <2.59 mmol/L (P<0.001 for both targets; 
Figure 2), and apo B levels of <0.9 and <0.8 g/L 
(P=0.004 and P<0.001, respectively; Figure 2) at 
study endpoint in the EZE/SIMVA group than in 
the ROSUVA group. 
Safety and Tolerability
Treatment with EZE/SIMVA and ROSUVA was 
generally well tolerated in obese and non-obese 
patients. The incidences and types of clinical 
AEs were generally consistent across the patient 
subgroups and treatment groups (Table 4). 
There were no clinically meaningful differences 
between obese and non-obese patients with 
respect to the incidences of hepatobiliary-related, 
gallbladder-related, gastrointestinal-related, 
or allergic reaction AEs. Presumed consecutive 
elevations in alanine aminotransferase 
and/or aspartate aminotransferase values 
≥3 times ULN were observed in one patient 
receiving EZE/SIMVA in each of the subgroups; 
no such elevations were seen in patients taking 
ROSUVA in either subgroup. There were no 
reports of creatine kinase elevations >10 times 
ULN in any patients.
Comb Prod Ther (2011)  1(1):001 7
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Table 3. Baseline characteristics for randomized obese and non-obese patients (continued on next page).
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Table 3. (continued) Baseline characteristics for randomized obese and non-obese patients. 
Data are expressed as least squares mean (95% CI) unless otherwise noted.
*618 patients were randomized; number of patients shown excludes data for one randomized patients with unknown body 
mass index at baseline.  
†Ranges shown represent the range of patients numbers that contribute to calculations for each parameter.  
‡Data are expressed as median (95% CI).  
§P<0.001 vs. ROSUVA; ||P=0.053 vs. ROSUVA.
Apo B=apolipoprotein; EZE/SIMVA=ezetimibe/simvastatin combination tablet; HDL-C=high-density lipoprotein 
cholesterol; hs-CRP=high-sensitivity C-reactive protein; LDL-C=low-density lipoprotein cholesterol;  
LDL-C:HDL-C=ratio of LDL-C/HDL-C; ROSUVA=rosuvastatin; TC=total cholesterol; TG=triglycerides. 
hs-CRP, mg/dL‡ 































Figure 1. Least squares (LS) mean percent change from 
baseline in low-density lipoprotein cholesterol (LDL-C) 
(A), total cholesterol, non-high-density lipoprotein 
cholesterol (HDL-C), apolipoprotein B (apo B) (B), and 
triglycerides (median) and HDL-C (C) for the overall 
population and within patient subgroups defined by the 
presence/absence of obesity. The numbers of patients 
shown for each parameter represent the full-analysis set 
population. 
EZE/SIMVA=ezetimibe/simvastatin; 






























P-value is for EZE/SIMVA 10/20 mg vs. ROSUVA 10mg.
Treatment by subgroup interaction P-value=0.533.
304n= 297
P<0.001


































Treatment-by-subgroup interaction P-values for TG, non-HDL-C, 















































Treatment-by-subgroup interaction P-values for TG, non-HDL-C 
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DISCUSSION
In this population of hypercholesterolemic 
obese and non-obese patients at high 
cardiovascular risk who failed to reach their 
minimum recommended LDL-C level of 
<4.14 mmol/L while taking statin monotherapy, 
switching to EZE/SIMVA 10/20 mg resulted in 
significantly greater improvements in LDL-C,





























Number of patients (%)* 
    With one or more clinical AEs 
With treatment-related clinical AEs† 
With serious clinical AEs 




 Clinical AEs 
 Treatment-related clinical AEs† 
 Serious clinical AE 
  Serious treatment-related clinical 
AEs†
    Hepatobiliary-related AEs 
Gallbladder-related AEs 
Gastrointestinal-related AEs 
Allergic reaction or rash AEs  
Consecutive ≤3× ULN elevations in 
































































































Table 4. Summary of adverse experiences (AEs).
*Excludes one randomized patient from the EZE/SIMVA group with unknown body mass index at baseline.  
†Determined by study investigator to be related to the drug.  
‡One death that occurred from a traumatic brain injury and subarachnoid hemorrhage was deemed not related to study drug 
by the investigator.  
§Includes subjects with two consecutive measurements for ALT and/or AST ≥3× ULN and a single, last measurement ≥3× ULN 
or a measurement ≥3× ULN followed by a measurement <3× ULN that was taken more than 2 days after the last dose of 
study medication.
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CK=creatine kinase; EZE/SIMVA=ezetimibe/
simvastatin; ROSUVA=rosuvastatin; ULN=upper limit of normal. 
ROSUVA 10 mg. Switching to combination 
therapy resulted in consistent changes in LDL-C,
TC, non-HDL-C, and apo B, irrespective of 
obesity status. The absence of significant 
treatment-by-subgroup interaction terms for 
all LDL-C and non-HDL-C values analyzed 
indicate that the proportions of patients 
attaining these levels within both subgroups 
were generally consistent with those seen in the 
overall analysis population.
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In addition to elevated plasma LDL-C 
levels, hypertriglyceridemia and high levels 
of apo B have been shown to contribute 
to increased cardiovascular risk.11,12 Obese 
patients tend to present with higher levels of 
small dense LDL particles in conjunction with 
hypertriglyceridemia and lower HDL-C levels 
compared with the general population.13 Both 
EZE/SIMVA and ROSUVA produced significant 
reductions from baseline in TG and apo B in the 
overall population and within the subgroups. 
The incremental between-group reductions in 
TG and apo B seen in the overall population 
were borderline statistically significant for TG 
(P=0.053) and significant for apo B (P<0.001), 
favoring EZE/SIMVA therapy. Treatment with 
EZE/SIMVA appeared numerically more effective 
than ROSUVA at lowering both TG and apo B 
within each subgroup; however, except for a 
significantly greater improvement in apo B 
with EZE/SIMVA versus ROSUVA therapy in 
non-obese patients, the between-group 
differences in TG and apo B did not reach 
statistical significance for either subgroup. 
The finding of non-significant between-group 
differences in TG and apo B may be due to the 
inherent variability associated with TG values 
and the limited number of patients contributing 
to the subgroup analyses. Nevertheless, the 
lack of significant treatment-by-subgroup 
Figure 2. Proportion of patients who achieved low-density 
lipoprotein cholesterol (LDL-C) levels <2.59 mmol/L 
(100 mg/dL) and <1.81 mmol/L (70 mg/dL) (A), non-
high-density lipoprotein cholesterol (HDL-C) levels  
<3.37 mmol/L (130 mg/dL) and <2.59 mmol/L  
(100 mg/dL) (B), and apolipoprotein B (apo B) levels  
<0.9 g/L  (90 mg/dL) and <0.8 g/L (80 mg/dL) (C) at 
study endpoint for the overall population and within 
patient subgroups defined by the presence/absence of 
obesity.  The numbers of patients shown for each parameter 





































e treatment by subgroup interaction P-values for LDL-C goals 

























































































e treatment by subgroup interaction P-values for non-HDL-C goals 






















































































e treatment by subgroup interaction P-values for apo B goals <0.9 g/L and 
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interactions for TG and apo B suggests the 
treatment effects seen in both subgroups were 
consistent with those in the overall population, 
where significant treatment differences in favor 
of EZE/SIMVA were observed. 
Low plasma HDL-C levels, a characteristic 
frequently associated with abdominal obesity 
and insulin resistance,14,15 has been shown to be 
a strong and independent risk factor for future 
cardiovascular events and mortality.16 HDL 
particles are believed to be antiatherogenic 
by virtue of facilitating cholesterol transport 
to the liver following efflux from peripheral 
tissues, and also by exerting antioxidant, 
antithrombotic, and anti-inflammatory 
effects.17,18 In the current study, treatment with 
EZE/SIMVA or ROSUVA produced significant 
increases from baseline in HDL-C, both in 
the overall study population and non-obese 
patients; however, neither treatment led to 
significant improvements in HDL-C within 
the obese subgroup. The magnitude of the 
differences, however, was very small and the 
lack of significant changes from baseline seen 
with both individual therapies in the obese 
population may be due to the small number 
of patients contributing to the analysis. 
There were no significant between-treatment 
differences in HDL-C in the overall population 
or within either subgroup, indicating that 
EZE/SIMVA and ROSUVA produced similar 
effects on HDL-C, irrespective of the patient 
population examined. 
Plasma hs-CRP is an inflammatory biomarker 
that has been shown to independently 
predict cardiovascular events and contribute 
to an individual’s global risk classification, 
irrespective of plasma LDL-C levels.19 Low grade 
inflammation, as measured by elevated plasma 
levels of hs-CRP, is a feature of central obesity.20
Additionally, hs-CRP has been shown to have 
deleterious effects on vascular biology.21 Previous 
studies suggest that statins lower hs-CRP levels 
independent of LDL-C.22,23 Furthermore, 
EZE 10 mg administered in combination with 
statins has been shown to significantly enhance 
hs-CRP reductions beyond what is seen with 
statin monotherapy.24 In the current analysis, 
treatment with EZE/SIMVA and ROSUVA did 
not produce significant within- or between-
group changes from baseline in hs-CRP either 
in the overall study population or within 
the subgroups. It is not clear why neither 
EZE/SIMVA 10/20 mg nor ROSUVA 10 mg 
produced significant reductions in hs-CRP 
in the current study; however, the inherent 
variability in hs-CRP within the population and 
the limited sample size may have contributed to 
this finding. Most publications demonstrating 
significant effects of statins and ezetimibe plus 
statin combination therapy on hs-CRP have 
come from studies enrolling larger numbers of 
patients or analyses conducted in pooled studies 
or databases.22,24
Lowering LDL-C is the primary aim of lipid-
lowering therapy patients with high risk for CVD. 
Irrespective of the obesity status of the patients, 
the reduction in LDL-C seen in the present 
study following treatment with EZE/SIMVA 
10/20 mg significantly exceeded that seen for 
ROSUVA 10 mg at study end. The enhanced 
LDL-C-lowering efficacy of EZE/SIMVA versus 
ROSUVA resulted in significant increases in the 
percentages of obese and non-obese patients 
achieving recommended LDL-C levels of <2.59 
and <1.81 mmol/L. Recent literature suggests 
that non-HDL-C and apo B are more accurate 
markers of CHD risk25 and treatment targets,26
especially in cardiometabolic risk patients, 
including those with obesity.7 In the current 
study, treatment with EZE/SIMVA 10/20 mg 
produced significantly greater reductions than 
ROSUVA 10 mg in non-HDL-C and apo B among 
patients in both subgroups. Furthermore, a 
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significantly higher percentage of patients in 
both subgroups achieved specified levels of 
non-HDL-C (<3.37 and <2.59 mmol/L) and apo 
B (<0.9 and <0.8 g/L) with EZE/SIMVA versus 
ROSUVA. 
The overall safety and tolerability profile 
of EZE/SIMVA was similar to that seen with 
ROSUVA in obese and non-obese patients. There 
was no evidence of a clinically meaningful 
difference in the incidences of AEs, including 
those related to muscle or liver toxicity in 
patients taking either EZE/SIMVA or ROSUVA.
These  co l lec t ive  f indings  suggest 
that  combinat ion therapy with the 
minimum recommended starting dose of 
EZE/SIMVA (10/20 mg) may allow more 
obese and non-obese patients to achieve 
recommended LDL-C, non-HDL-C, and apo B
levels compared with the starting dose of 
ROSUVA monotherapy (10 mg), without 
increased safety/tolerability concerns. The 
results of this analysis in obese and non-obese 
patients are consistent with previous reports 
showing the consistency in the lipid- and 
lipoprotein-lowering effects of EZE/SIMVA 
therapy in diabetic and metabolic syndrome 
patients who frequently are also obese.10,27-30 
The finding that EZE/SIMVA therapy 
effectively treats dyslipidemia, irrespective of 
obesity status, may be of particular interest 
because the lipoprotein profile in obese patients 
is similar to that seen in patients with chronic 
kidney disease. The recent Study of Heart and 
Renal Protection (SHARP) trial demonstrated 
that EZE/SIMVA 10/20mg safely reduced 
cardiovascular events in patients with advanced 
chronic kidney disease.31 The observed reduction 
in cardiovascular risk was consistent with what 
would be predicted based on the achieved LDL-C 
reductions. Whether the beneficial effects of 
combination therapy with EZE and a statin 
will translate to improved outcomes in patients 
with coronary heart disease is currently being 
evaluated in the ongoing IMProved Reduction 
of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT trial).32,33
The present analysis has several limitations 
that should be considered when interpreting 
the findings. First, this was an exploratory post-
hoc analysis, and statistical comparisons were 
made without adjustment for multiplicity; 
thus, increasing the probability of false positive 
observations (eg, spurious findings of statistical 
significance). The small number of obese 
patients enrolled in this study is a further 
limitation, which may have contributed to false 
negative observations (eg, absence of statistical 
significance within subgroups). Finally, 
patients were classified as obese or non-obese 
on the basis of baseline BMI values because 
other markers (waist circumference, waist-to-
hip measurements) of visceral adiposity were 
not recorded. As a result, it is not certain that 
the findings presented in this paper can be 
extrapolated to patients who are classified as 
visceral obese based on waist circumference and 
waist-to-hip ratio measurements.
CONCLUSION
In this post-hoc analysis of high-risk patients 
with elevated LDL-C, despite prior use of 
statin therapy, switching to EZE/SIMVA 10/20 
mg versus ROSUVA 10 mg provided superior 
reductions in LDL-C, TC, and non-HDL-C in 
obese and non-obese patients.
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